AZ cuts 500 contract sales jobs

AstraZeneca trimmed its U.S. contract sales force by about 500 following setbacks with its Exanta blood-thinner and lung cancer drug Iressa.
An AZ spokesman maintained the cuts were not product related, however.
"Such employees are used to get the flexibility to adapt to changing market situations and to manage short-term costs," AZ spokesman Steve Brown said in a report. Contract sales employees are used to "sell the medium-sized, more mature brands," he said.
Analysts expected both Iressa and Exanta to generate more than $1 billion in peak annual sales. But in October, the FDA refused to approve Exanta and last month, AZ published results showing Iressa failed to help cancer patients live longer. AZ shares fell 30 percent last year.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.